Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma

Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma
Conditions:   Unresectable Melanoma;   Metastatic Melanoma
Intervention:   Biological: Lifileucel
Sponsor:   Iovance Biotherapeutics, Inc.
Available

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 2, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments